Shenzhen EFUNG Investment Management Enterprise is an institution that invests in professional biomedical industries.
Business Model:
Revenue: $0
Employees: 0-0
Address:
City:
State:
Zip:
Country:
Shenzhen EFUNG Investment Management Enterprise L. P. is one of China&s;s earliest institutions investing in professional biomedical industries. Their strong research team and great investment returns made us won &s;The Most Pioneering VC Institution” &s;The Most Dynamic Pharmaceutical VC Institution in China&s; and &s;The Top Ten VC Institutions in Shenzhen&s;. With this influence, EFUNG has drawn a lot of attention from the medical and life science industry. And it is interviewed by Nature, which is the most authoritative science magazine in the world. Over a decade of years, they have been focusing on the medical and health industry, especially the VC and PE investment business of novel drugs and high-end medical devices. The mission of EFUNG is to drive the industrialization of medical researches by capital and to gain rich returns to investors. EFUNG has deeply screened and invested in more than 20 domestic and international premium enterprises, such as Chipscreen Biosciences, Frontier Biotechnologies, Ascentage Pharma, Lifotronic, Aridis Pharmaceuticals, and Centrexion.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
1/2022 | West Lake Omi | Seed Round | - |
5/2010 | Rainjet | Series A | 1.5M |
6/2018 | Chipscreen | Venture Round | - |
6/2018 | Centrexion | Venture Round | - |
4/2020 | SiBionics | Series B | 28.4M |
7/2019 | TriArm Therapeutics | Series A | 0 |
12/2021 | BioInno | Series A | - |
3/2022 | CellOrigin Biotech | Venture Round | 0 |
1/2023 | JGene Biotechnology | Angel Round | - |
7/2012 | UNIHZ TECHNOLOGY | Angel Round | 469.6k |
11/2020 | Biostar Technologies | Series E | 890M |
1/2022 | Cloudbreak Therapeutics | Series C | 0 |
3/2021 | Gensciences | Series B | - |
8/2015 | Ascentage Pharma | Series A | 15.5M |
12/2022 | Maijing Gene | Series C | - |
2/2023 | Turno | Series A | 0 |
1/2022 | Atom Bioscience &a; Pharmaceutical | Series C | 45M |
11/2021 | JGene Biotechnology | Angel Round | - |
1/2018 | KBP Biosciences | Series A | 0 |
12/2021 | Kind Pharmaceutical | Series B | 50M |
3/2020 | Harbour Biomed | Series B | 75M |
3/2020 | OBiO Technology | Series B | 15M |
6/2018 | Frontier Biotechnologies | Venture Round | - |
6/2018 | Lifotronic | Venture Round | - |
11/2022 | Trinomab | Venture Round | 104.7M |
7/2020 | OBiO Technology | Series C | 28.5M |
12/2020 | Raynovent | Series B | 42.8M |
12/2021 | XuanZhu Pharma | Series B | 0 |
6/2018 | Resverlogix | Post-IPO Equity | 10.4M |
7/2020 | InnerMedical | Series B | - |
7/2019 | Zhongyianke Biotech | Series A | 36M |
12/2018 | Tactiva Therapeutics | Series A | 35M |
9/2020 | Jifu Medical | Series C | 0 |
10/2019 | WeMed | Series C | - |
12/2021 | CirCode | Seed Round | 20M |
10/2019 | Elicio Therapeutics | Series B | 33M |
6/2018 | Aridis Pharmaceuticals | Venture Round | - |
1/2023 | Raynovent | Series C | 53.8M |
5/2022 | JSD | Series A | - |
11/2012 | Castdservo | Angel Round | 481.6k |
10/2020 | 3D Medicines | Venture Round | 0 |
1/2023 | IASO Biotherapeutics | Series C | 73.8M |
2/2022 | JGene Biotechnology | Seed Round | - |
5/2022 | JSD | Series A | - |
3/2022 | CellOrigin Biotech | Venture Round | 0 |
1/2022 | West Lake Omi | Seed Round | - |
1/2022 | Atom Bioscience &a; Pharmaceutical | Series C | 0 |
1/2022 | Cloudbreak Therapeutics | Series C | 0 |
12/2021 | XuanZhu Pharma | Series B | 0 |
12/2021 | Kind Pharmaceutical | Series B | 0 |
12/2021 | BioInno | Series A | - |
12/2021 | CirCode | Seed Round | 0 |
11/2021 | JGene Biotechnology | Angel Round | - |
Name | Price |
---|
Name | Size | Announced Date |
---|